Replimune Group, Inc. (REPL)
2.30
+0.35
(+17.95%)
USD |
NASDAQ |
Apr 15, 16:00
2.24
-0.06
(-2.61%)
After-Hours: 20:00
Replimune Group Research and Development Expense (Annual) : 191.22M for March 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ANI Pharmaceuticals, Inc. | 51.66M |
| Phathom Pharmaceuticals, Inc. | 32.78M |
| REGENXBIO, Inc. | 212.68M |
| Bristol Myers Squibb Co. | 9.492B |
| Organon & Co. | 366.00M |